Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07574645 · ClinicalTrials.gov registry record
Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry
A clinical trial, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
NCT07574645: Recruiting study, sponsored by Thomas Jefferson University.
NCT07574645 is a clinical trial that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07574645 is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
Given the lack of large multicenter datasets in the context of Spinal arteriovenous fistula, the strength of the evidence surrounding this rare disease is limited. SPIDER hence aims to address that by compiling patient-level data from centers all around the world.
Primary Outcome
Complete surgical/endovascular obliteration of the fistula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2026-05 |
What NCT07574645 shows while recruiting
NCT07574645 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07574645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07574645 about?
NCT07574645 is a clinical study titled "Spinal Dural Arteriovenous Fistula International Data and Outcomes Registry". Given the lack of large multicenter datasets in the context of Spinal arteriovenous fistula, the strength of the evidence surrounding this rare disease is limited. SPIDER hence aims to address that by compiling patient-level data from centers all around the world.
What is the current status of trial NCT07574645?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2026-01-05. Estimated completion is 2026-05.
Who is sponsoring clinical trial NCT07574645?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI